Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/36222
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSandes, Alex Freire [UNIFESP]
dc.contributor.authorKerbauy, Daniela Márcia Bahia [UNIFESP]
dc.contributor.authorMatarraz, Sergio
dc.contributor.authorChauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
dc.contributor.authorLopez, Antonio
dc.contributor.authorOrfao, Alberto
dc.contributor.authorYamamoto, Mihoko [UNIFESP]
dc.date.accessioned2016-01-24T14:31:36Z-
dc.date.available2016-01-24T14:31:36Z-
dc.date.issued2013-05-01
dc.identifierhttp://dx.doi.org/10.1002/cyto.b.21087
dc.identifier.citationCytometry Part B-clinical Cytometry. Hoboken: Wiley-Blackwell, v. 84B, n. 3, p. 157-166, 2013.
dc.identifier.issn1552-4949
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/36222-
dc.description.abstractBackground. Quantification of bone marrow (BM) blasts by cytomorphology is essential for the diagnosis of myelodysplastic syndromes (MDS). Owing to its subjectivity and the potential impact of dysplastic features on accurate identification of blast cells, more objective approaches are required, multiparameter flow cytometry (MFC) being a particularly promising approach in this regard. However, no consensus exists about the optimal combination of markers and strategy to be used. Methods. BM blast counts from 74 MDS patients were evaluated by morphology versus four different MFC phenotypic criteria: CD34+, CD34+ and/or CD117+, CD34+, and/or CD117+HLA-DR+, and CD34+ and CD117+HLA-DR+ plus CD64+CD14/lo cells. for each criterium, the percentage of blasts was calculated using either all BM nucleated cells or non-erythroid CD45+ cells as denominator. Results. the number of CD34+ and/or CD117+HLA-DR+cells showed the highest correlation and agreement with morphological counts, only a minor proportion of cases being misclassified by MFC vs. morphology for the >5% and >10% classification thresholds. in turn, a CD34+ phenotype was insufficient to correctly identify and quantify blasts. Conversely, usage of non-erythroid BM cells as denominator, or inclusion of CD34+ and/or CD117+HLA-DR+ plus CD64+CD14lo cells were both associated with overestimated blast counts. Conclusions. Quantification of CD34+ and/or CD117+HLA-DR+ cells (from all nucleated BM cells) by MFC is an efficient method for the enumeration of blasts in MDS. However, caution should be taken with replacing morphology by MFC blast counts; its combined use may rather provide complementary information increasing the accuracy and reproducibility of BM blast cell counts in these patients. (c) 2013 International Clinical Cytometry Societyen
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipFADA UNIFESP
dc.description.sponsorshipRTICC
dc.description.sponsorshipFondo Europeo de Desarrollo Regional (FEDER), the Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain
dc.format.extent157-166
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofCytometry Part B-clinical Cytometry
dc.rightsAcesso aberto
dc.subjectmyelodysplastic syndromesen
dc.subjectblast cell counten
dc.subjectflow cytometryen
dc.subjectmorphologyen
dc.titleCombined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromesen
dc.typeArtigo
dc.rights.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Salamanca
dc.description.affiliationUniversidade Federal de São Paulo UNIFESP EPM, Div Hematol, Dept Clin & Expt Oncol, Escola Paulista Med, São Paulo, Brazil
dc.description.affiliationUniv Salamanca, CSIC USAL, Ctr Invest Canc IBMCC, E-37008 Salamanca, Spain
dc.description.affiliationUniv Salamanca, Serv Citometri, IBSAL, E-37008 Salamanca, Spain
dc.description.affiliationUniv Salamanca, Dept Med, E-37008 Salamanca, Spain
dc.description.affiliationUnifespUniversidade Federal de São Paulo UNIFESP EPM, Div Hematol, Dept Clin & Expt Oncol, Escola Paulista Med, São Paulo, Brazil
dc.description.sponsorshipIDFAPESP: 05/57792-0
dc.description.sponsorshipIDCNPq: 142968/2006-4
dc.description.sponsorshipIDCAPES: PDEE BEX 1025/05-8
dc.description.sponsorshipIDRTICC: RD12/0036/0048
dc.identifier.doi10.1002/cyto.b.21087
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000318041900005
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.